"The ALS Society of Canada is launching a new virtual series for people living with ALS, their families, caregivers, and anyone close to someone living with the disease who might have questions...
A new study finds that rising placebo responses may play a part in the increasingly high failure rate for clinical trials of drugs designed to control chronic pain caused by nerve damage.
Badly designed studies may lead to the efficacy of drugs being overestimated and money being wasted on trials that prove fruitless, according to a new study from McGill University in Canada.
Standards for authorizing first-time trials of drugs in humans are lax, and should be strengthened in several ways, McGill University researchers argue in a paper published today in Nature.